Skip to main content

Cancer Chemotherapy and Pharmacology

Ausgabe 2/2009

Inhalt (21 Artikel)

Original Article

cis-3, 4′, 5-Trimethoxy-3′-aminostilbene disrupts tumor vascular perfusion without damaging normal organ perfusion

David Durrant, Frank Corwin, Daniele Simoni, Ming Zhao, Michelle A. Rudek, Fadi N. Salloum, Rakesh C. Kukreja, Panos P. Fatouros, Ray M. Lee

Open Access Original Article

Preclinical efficacy spectrum and pharmacokinetics of ixabepilone

Francis Y. F. Lee, Richard Smykla, Kathy Johnston, Krista Menard, Kelly McGlinchey, Russell W. Peterson, Amy Wiebesiek, Gregory Vite, Craig R. Fairchild, Robert Kramer

Open Access Original Article

Her2/neu signaling blockade improves tumor oxygenation in a multifactorial fashion in Her2/neu+ tumors

Matthew E. Hardee, Rose J. Eapen, Zahid N. Rabbani, Matthew R. Dreher, Jeffrey Marks, Kimberly L. Blackwell, Mark W. Dewhirst

Original Article

Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults

Divya Menon-Andersen, John T. Mondick, Bhuvana Jayaraman, Patrick A. Thompson, Susan M. Blaney, Mark Bernstein, Mason Bond, Martin Champagne, Michael J. Fossler, Jeffrey S. Barrett

Original Article

Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered?

Richard M. Logan, Andrea M. Stringer, Joanne M. Bowen, Rachel J. Gibson, Stephen T. Sonis, Dorothy M. K. Keefe

Original Article

Phase I dose escalation study of docetaxel with a fixed dose of S-1 in combination chemotherapy for advanced gastric cancer

Yeul Hong Kim, Hee Yeon Seo, Yoon Tae Jeen, Hoon-Kyo Kim, Byoung Yong Shim, Jinmo Yang

Original Article

Phase I/II trial of combination therapy with S-1 and weekly paclitaxel in patients with unresectable or recurrent gastric cancer

Seisuke Inada, Takashi Tomidokoro, Hiroyuki Fukunari, Tomomi Sato, Toru Hatano, Atsushi Nishimura, Yasuyuki Kawauchi, Keiya Nikkuni, Takeaki Shimizu, Toshiteru Sato, Masahiko Yanagi, Satoru Takahashi, Hideki Yoshida, Minoru Sugita, Tetsuji Hayashi

Original Article

Central nervous system metastases in a cohort of metastatic breast cancer patients treated with trastuzumab

E. Montagna, G. Cancello, D. D’Agostino, R. Lauria, V. Forestieri, A. Esposito, L. Silvestro, A. Accurso, S. De Placido, M. De Laurentiis

Original Article

Use of cholesterol-rich nanoparticles that bind to lipoprotein receptors as a vehicle to paclitaxel in the treatment of breast cancer: pharmacokinetics, tumor uptake and a pilot clinical study

Luís A. Pires, Roberto Hegg, Claudete J. Valduga, Sílvia R. Graziani, Débora G. Rodrigues, Raul C. Maranhão

Original Article

Human concentrative nucleoside transporter 3 is a determinant of fludarabine transportability and cytotoxicity in human renal proximal tubule cell cultures

Adam N. Elwi, Vijaya L. Damaraju, Michelle L. Kuzma, Stephen A. Baldwin, James D. Young, Michael B. Sawyer, Carol E. Cass

Original Article

NSC606985, a novel camptothecin analog, induces apoptosis and growth arrest in prostate tumor cells

Chen Tan, Li-Qun Cai, Wendy Wu, Yaming Qiao, Julianne Imperato-McGinley, Guo-Qiang Chen, Yuan-Shan Zhu

Original Article

A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer

Chigusa Morizane, Takuji Okusaka, Junji Furuse, Hiroshi Ishii, Hideki Ueno, Masafumi Ikeda, Kohei Nakachi, Mina Najima, Takashi Ogura, Eiichiro Suzuki

Original Article

Considerations for intravascular administration of oncolytic herpes virus for the treatment of multiple liver metastases

Naohiro Nomura, Hideki Kasuya, Izuru Watanabe, Toshio Shikano, Takashi Shirota, Makoto Misawa, Hiroyuki Sugimoto, Naohito Kanazumi, Shuji Nomoto, Shin Takeda, Akimasa Nakao

Original Article

A phase I pharmacokinetic study of hypoxic abdominal stop-flow perfusion with gemcitabine in patients with advanced pancreatic cancer and refractory malignant ascites

Andrea Kuemmerle, Laurent A. Decosterd, Thierry Buclin, Danielle Liénard, Roger Stupp, Pierre-Guy Chassot, François Mosimann, Ferdy Lejeune

Original Article

Dexrazoxane protects against doxorubicin-induced cardiomyopathy: upregulation of Akt and Erk phosphorylation in a rat model

Ping Xiang, Hai Yan Deng, Karen Li, Guo-Ying Huang, Yuan Chen, Liu Tu, Pak Cheung Ng, Nga Hin Pong, Hailu Zhao, Lei Zhang, Rita Yn Tz Sung

Original Article

A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma

L. C. Scott, J. C. Yao, A. B. Benson III, A. L. Thomas, S. Falk, R. R. Mena, J. Picus, J. Wright, M. F. Mulcahy, J. A. Ajani, T. R. J. Evans

Short Communication

Administration of oxaliplatin to a pregnant woman with rectal cancer

Michael Gensheimer, Catherine A. Jones, Cornelia R. Graves, Nipun B. Merchant, A. Craig Lockhart

Open Access Short Communication

Altered cyclophosphamide and thiotepa pharmacokinetics in a patient with moderate renal insufficiency

Corine Ekhart, J. Martijn Kerst, Sjoerd Rodenhuis, Jos H. Beijnen, Alwin D. R. Huitema

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.